[EN] 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS [FR] COMPOSÉS 2-HÉTÉROCYCLYLAMINO PYRAZINES SUBSTITUÉES EN POSITION 6 EN TANT QU'INHIBITEURS DE CHK-1
[EN] 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS [FR] COMPOSÉS 2-HÉTÉROCYCLYLAMINO PYRAZINES SUBSTITUÉES EN POSITION 6 EN TANT QU'INHIBITEURS DE CHK-1
6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS
申请人:Braganza John Frederick
公开号:US20110144084A1
公开(公告)日:2011-06-16
The present invention is directed to compounds of formula (I),
and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.
6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS
申请人:Pfizer Inc.
公开号:EP2328890A1
公开(公告)日:2011-06-08
US8518952B2
申请人:——
公开号:US8518952B2
公开(公告)日:2013-08-27
[EN] INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS<br/>[FR] DÉRIVÉS D'INDOLIZINE POUR LE TRAITEMENT DE TROUBLES MÉDIÉS PAR TRPM3
申请人:[en]KATHOLIEKE UNIVERSITEIT LEUVEN
公开号:WO2023230543A1
公开(公告)日:2023-11-30
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.